ALIM Alimera Sciences
- 3.650
- +0.170+4.89%
Alimera Sciences News
Express News | Alimera Sciences to Report First Quarter 2024 Financial Results on May 14, 2024, and Provide Corporate Update
Express News | Alimera Sciences Inc : Craig-Hallum Assumes Coverage With Buy Rating; Target Price $8: Craig-Hallum Assumes Coverage With Buy Rating; Target Price $8
Alimera Sciences Initiated at Buy by Maxim Group
Alimera Sciences Initiated at Buy by Maxim Group
Express News | Maxim Group Initiates Coverage On Alimera Sciences With Buy Rating, Announces Price Target of $10
The Top Stocks With Buying Pressure Across the Russell Universe - Jefferies
Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ATLANTA, March 20, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera" or the "Company"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners
Alimera Announces First Patient Randomized In Radiation Retinopathy Trial Being Conducted By The DRCR Retina Network
Alimera Announces First Patient Randomized In Radiation Retinopathy Trial Being Conducted By The DRCR Retina Network
Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network
Protocol AL is studying ILUVIEN or faricimab (6.0 mg) injections versus observation for the prevention of visual acuity loss due to radiation retinopathy ATLANTA, March 19, 2024 (GLOBE NEWSWIRE) --
Alimera Sciences Is Maintained at Buy by HC Wainwright & Co.
Alimera Sciences Is Maintained at Buy by HC Wainwright & Co.
Express News | HC Wainwright & Co. Maintains Buy on Alimera Sciences, Raises Price Target to $6
Alimera Sciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/08/2024 50.38% HC Wainwright & Co. $5 → $6 Maintains Buy 08/14/2023 25.31% HC Wainwright & Co. → $5 Rei
Buy Rating Affirmed for Alimera Sciences Amid Strong Financial Performance and Promising Clinical Trials
Q4 2023 Alimera Sciences Inc Earnings Call
Earnings Call Summary | Alimera Sciences(ALIM.US) Q4 2023 Earnings Conference
The following is a summary of the Alimera Sciences, Inc. (ALIM) Q4 2023 Earnings Call Transcript:Financial Performance:Alimera Q4 2023 reported a consolidated global net revenue of $26.3 million, up 8
Express News | Alimera Sciences Expects 2024 Revenue Over $105M Vs. $103.66M Consensus, And Greater Than 20% Adjusted EBITDA Margin
Alimera Sciences Sees 2024 Adjusted Ebitda Margin Topping 20% >ALIM
Alimera Sciences Sees 2024 Adjusted Ebitda Margin Topping 20% >ALIM
Express News | Alimera Sciences Q4 EPS $(0.07) Up From $(0.54) YoY, Sales $26.31M Beat $24.34M Estimate
Alimera Sciences 4Q Rev $26.3M >ALIM
Alimera Sciences 4Q Rev $26.3M >ALIM
Press Release: Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results
Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results Q4 Net Revenues up 88% to $26.3 million vs. Q4 2022 2023 Net Revenues up 49% to $80.8 million vs. 2022 Increases 2024 Revenue Guid
Earnings Scheduled For March 7, 2024
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million. • Stevanato Gr (NYSE:STVN) is likely to report quarte
Analysis
Price Target
No Data
